Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD.

Gavin C Donaldson¹, Terence AR Seemungal², John R Hurst¹, Jadwiga A Wedzicha¹

¹Academic Unit of Respiratory Medicine, UCL Medical School, Royal Free Campus, London, UK.

²Department of Clinical Medical Sciences, University of the West Indies, St. Augustine, Trinidad and Tobago.

Address for correspondence:

Dr Gavin Donaldson
Academic Unit of Respiratory Medicine
UCL Medical School
Royal Free Campus
Rowland Hill Street
Hampstead
London NW3 2PF
UK

Tel: +44 (0) 207 794 0500 extn 34308
Fax: +44 (0) 207 472 6141
e-mail: g.donaldson@medsch.ucl.ac.uk

Running head: COPD exacerbation and DFA.

Key words: COPD, exacerbations, peak expiratory flow, detrended fluctuation analysis, anti-cholinergic agent.

Abstract: 198

Word count: 3449

Tables 2
Figures 4

Funding: The London COPD Cohort is funded by the Medical Research Council, UK. The clinical trial of Tiotropium was funded by Boehringer Ingelheim.

Contributions: Conception and design, Analysis and interpretation, Drafting the manuscript for important intellectual content: GD TS JH JW.
ABSTRACT

Background: We investigated whether exacerbation frequency in COPD was related to an exponent $\alpha$ which quantifies self-similarity in daily peak expiratory flow (PEF) and is calculated using detrended fluctuation analysis (DFA).

Methods: We examined data from COPD patients who recorded increase in respiratory symptoms and post-bronchodilator PEF on daily diary cards. We also investigated PEF data from a double blind, placebo controlled trial of the anti-cholinergic agent, Tiotropium.

Findings: In the observational study there were 308 patients with COPD (195 male; mean (SD) age 68.3 years (8.4), FEV$_1$ 1.12 l (0.46), FEV1 % predicted 44.5 % (16.4)). The mean $\alpha$ over the first year was 0.944 (SD 0.19) and it was positively related to exacerbations per year ($p=0.009$). In the clinical trial, $\alpha$ was lower in COPD patients randomized to tiotropium, mean 0.87 (0.21, n=48) than on placebo, mean 0.95 (0.19, n=52; $p=0.035$). Power analysis showed that fewer patients would be required for clinical studies with $\alpha$ as the outcome measure than exacerbation frequency.

Interpretation: DFA shows that daily PEF in COPD has long-term correlations which is related to exacerbation frequency. Monitoring of PEF and use of $\alpha$ may result in smaller COPD patient sample sizes in trials.
Introduction

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway condition characterised by episodes of symptomatic deterioration termed exacerbations [1]. Exacerbations are a common cause of admission to hospital and thus costly to healthcare services [2]. Some COPD patients are susceptible to frequent exacerbations [3] and these frequent exacerbators have poorer quality of life [4], faster disease progression [5] and increased mortality [6].

Thus factors associated with frequent exacerbations are important, and several longitudinal studies have shown that within an individual patient exacerbation frequency is similar from one year to the next [3, 4, 7-9]. A number of therapeutic interventions reduce exacerbations, but clinical trials require a large number of randomised patients to be monitored to capture these relatively infrequent events. Thus, a measure of exacerbation risk that is responsive to therapy, would be useful both for clinical purposes and also for testing interventions in COPD.

There is growing evidence that signals from complex biological system can have fluctuations that exhibit long-range correlations [10, 11]. In other words, the signal is correlated with itself over a longer time scale [12]. This is referred to as self-similarity [13]. It can be quantified using a technique called detrended fluctuation analysis (DFA) [14, 15]. The technique has been applied by Frey and colleagues to peak expiratory flow (PEF) in asthma [16-18]. DFA has also been used in the study of respiratory impedance in asthma and COPD [19] and inter-breath intervals [15]. If the exponent α from DFA is equal to 0.5 then successive points in a time series have...
no relationship to each other. However, if $\alpha > 0.5$ then the time series has long-range correlations and points in the time-series are related to previous values. This has been described as the system having a memory which translates as the current situation being dictated by past events. A time series of daily PEF which has a high value of $\alpha$ has a smooth appearance whereas a low value of $\alpha$ will be associated with a rougher or jagged appearance.

Numerical models have shown that $\alpha$ is significantly related to the frequency of asthmatic events and data from a clinical trial showed that it responded to therapeutic intervention with a long-acting $\beta_2$-agonist [17]. PEF, though easily measured, is not routinely used for diagnostic or monitoring purposes in COPD, and changes in PEF are relatively small at COPD exacerbation [20].

We have examined the scaling exponent $\alpha$ of PEF in COPD patients with moderate to severe disease, and related it to exacerbation frequency and FEV$_1$ reversibility. In addition, we carried out a sensitivity analysis and excluded PEF data collected when the patients were experiencing an exacerbation to rule out the possibility that greater PEF variability during exacerbations was the source of the relationship between $\alpha$ and exacerbation frequency. We also examined PEF during a double-blind, placebo controlled trial of the long-acting anti-cholinergic bronchodilator Tiotropium. To assess the utility of $\alpha$ as a marker of exacerbation frequency we calculated the number of patients required to power a clinical trial with the primary endpoint either exacerbation frequency or $\alpha$.

Methods
London COPD cohort

Patients.

We examined data from 308 COPD patients enrolled in the London COPD cohort who had contributed data for at least one year, between 1st November 1995 and 31st December 2009. These COPD patients have been the subject of previous publications relating to exacerbations [4, 5, 7, 8] but the current analysis and its interpretation are completely novel. COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV$_1$) < 80% predicted for age, height and sex [21], and a FEV$_1$/FVC (forced vital capacity) ratio < 0.7. Patients with significant respiratory disease other than COPD were excluded.

The study had approval from the East London and City Research Ethics Committee and Royal Free Hospital NHS Trust Ethics Committee. Patients provided written informed consent.

Recruitment.

At recruitment, a history was taken of smoking habits (pack years of smoking and current smoking status). Measurements were made of FEV$_1$ and FVC by a routinely calibrated rolling seal spirometer (Sensor Medic Corp. Yorba Lindo, CA. USA) or volumetric storage spirometer (Vitalograph 2160, Maids Moreton, Buckingham UK). During the follow-up of the patients, reversibility of FEV$_1$ to 400 mcg of the
bronchodilator (BD) salbutamol was measured in 276 of the 308 patients and calculated as \((\text{post-BD FEV}_1 - \text{pre-BD FEV}_1)/\text{pre-BD FEV}_1 \times 100\).

**Monitoring and diagnosis of exacerbation**

Patients were instructed to record each morning on daily diary cards any increase over normal levels in their respiratory symptoms. Symptoms were classified as major and minor. Major symptoms were dyspnoea, sputum purulence or increased sputum volume and minor symptoms were coryza (nasal discharge/congestion), wheeze, sore throat and cough. Patients also manually recorded the best of three daily morning post-medication PEF measurements (Mini-Wright peak flow meter; Clement Clarke International Ltd., Harlow, UK). The mean PEF over the initial 365 days was calculated along with a coefficient of variation. The equations of Garcio-Rio et al. [22] were used to express PEF as a percentage of the predicted value.

Onset of exacerbation was identified as in our previous studies as the first of two or more consecutive days with increase in either two major symptoms or one major and one minor symptom [4, 5]. Occasionally exacerbations were identified when no symptoms were recorded but the patient was admitted to hospital or by questioning at clinic visits about primary care treatment [4, 5]. Exacerbation frequency was calculated as the total number of exacerbations divided by the observation time in years.

**Exacerbation recovery**
Exacerbation duration was defined as the number of days post exacerbation onset that any symptoms were still recorded, with the end of the recovery period defined as two consecutive symptom free days. The maximum duration of an exacerbation was capped at 100 days.

**Statistical analysis**

Data were analyzed with STATA 8.2 (Stata Corporation, Texas, USA). Normally distributed data were expressed as mean and standard deviation (SD) and skewed data as median and inter-quartile range (IQR), and comparisons made as appropriate by t-test or Wilcoxon signed rank test. Relationships with exacerbation frequency as the dependent variable were assessed by negative binomial regression that allows for over-dispersion in the dependent variable [23] and FEV₁ reversibility with ordinary least-squares linear regression.

**Detrended fluctuation analysis (DFA)**

The first 365 days of PEF recordings was assessed with detrended fluctuation analysis [17, 24]. The PEF series of length k was integrated as follows:

\[ y(k) = \sum_{i=1}^{k} (x(i) - \bar{x}) \]

The integrate time series was then divided into equally sized non-overlapping windows of length w. A linear regression line was fitted through the data in each window and the time series locally detrended by subtracting the regression line from the data. The root-mean-square fluctuation F(w) of the integrated and detrended time series was calculated for different values of w(ranging from 4\(^{th}\) to 24\(^{th}\) of the
time series), as
\[
F(w) = \sqrt{\frac{1}{N} \sum_{k=1}^{N} [y(k) - y_w(k)]^2}
\]
and the scaling exponent (α) obtained as the slope of a straight line fit to F(w) against w on a log–log plot, as
\[
F(w) \propto w^\alpha
\]
Figure 1 illustrates and explains DFA using hypothetical of PEF time series. Gaps in the time series where the patient failed to record data were retained as these occur in normal patient monitoring.

Sensitivity to PEF during exacerbation.
To exclude the possibility that any relationship between α and exacerbation frequency was due solely to PEF during exacerbations, sections of data from 7 days before onset to 7 days after exacerbation recovery were removed. The signal was then stitched back together. This splicing procedure does not affect the scaling behavior of positively correlated signals (1.5> α>0.5) [14].

Randomized control trial of Tiotropium.

Figure 2 shows the profile of the 100 of 142 randomized COPD patients who fully completed the trial of daily Tiotropium (per-protocol population). The PEF data from these patients (48 on Tiotropium and 52 on Placebo) was assessed by DFA. Full methodology and results of the trial are reported elsewhere [25] but PEF and
Exacerbations were assessed as described above. There was no overlap in the exacerbation data, PEF or patient characteristics in this study and data collected for the London Cohort.

Ethics approval for the placebo controlled trial of tiotropium was obtained from the East London and City Research Ethics committee and the trial was registered on ClinicalTrials.gov (NCT00405236).

During the early stages of the clinical trial, PEF in both drug and placebo groups rose. The initial 64 days of data were discarded as unrepresentative, leaving a round number of 300 days per patient for analysis, of which data were missing for on average only 2 days.

**Power analysis**

Estimation of the number of patients required in each treatment group with exacerbation frequency as the primary endpoint was made using the formulae described by Keene et al. [23]. In the calculation, the shape parameter used was from the TRISTAN study [26], and the mean exacerbation rates were those observed in the per-protocol population in the Tiotropium trial described above. The sample size required to detect the difference in $\alpha$ seen in the same population was calculated using the built-in Stata programme command sampsi [27].

**Role of the funding source**
As funder of the observational cohort, the Medical Research Council had no role in study design, data collection, analysis, interpretation, or writing of this report. The single-centre randomized placebo controlled trial of Tiotropium was funded by Boehringer Ingelheim. The trial was jointly conceived and designed, implemented by the authors, with monitoring and supervision by Boehringer Ingelheim. Data was jointly shared, but the analysis reported in this paper was performed solely by the authors.

All authors had full access to the data and gave permission for submission for publication.

**Results**

**Patient Characteristics**

The characteristics of the 308 COPD patients in the observational cohort (195 men) at recruitment are reported in Table 1. They had a mean age of 68.3 years (SD 8.4) and had moderate to severe COPD with a mean FEV\(_1\) of 44.5% predicted (SD 16.4); GOLD stages II, III and IV comprised 37.7%, 40.3% and 22.1% respectively. The cohort recorded daily diary card data for a total of 1077 days (range 365-4573); during which they experienced 2621 exacerbations with a median frequency of 2.04 per year (IQR 0.96 – 3.30).

**Relationships between α, exacerbation frequency and FEV\(_1\) bronchodilator reversibility.**
The mean $\alpha$ for all 308 COPD patients was 0.944 (SD 0.19). Tests for normality showed no significant skewness ($p=0.86$) or Kurtosis ($p=0.64$). $\alpha$ was significantly, but weakly, related to exacerbation frequency over the whole period of observation; negative binomial regression coefficient = 0.595 exacerbation per year per unit change in alpha (95% 0.15-1.0; $p=0.009$; pseudo $r^2=0.006$). The relationship remained significant after allowance for FEV$_1$ % predicted in the model (coefficient = 0.565 (95% 0.12-1.00; $p=0.012$)). $\alpha$ was also related to the exacerbation frequency during the first year of the study (coefficient = 0.661 exacerbation per year per unit change in alpha (95% CI 0.15-1.2)) and to number of exacerbations in the subsequent second year, after excluding 63 patients who completed less than 200 days in the second year (coefficient = 0.66 (95% CI 0.026-1.31; $p=0.041$)). These findings were unchanged if either a zero-inflated Poisson or zero-inflated negative binomial regression model was used instead of the negative binomial model.

**Relationship between $\alpha$ and FEV$_1$ bronchodilator reversibility.**

The mean reversibility to salbutamol was 8.1% (SD 13.1; n=276). $\alpha$ was linearly related to reversibility which increased by 13.4% per unit increase in $\alpha$ (95% CI 5.59 – 21.2; $p=0.001$). However, there was no relationship between reversibility and exacerbation frequency (negative binomial regression, $p=0.142$)

**Sensitivity of $\alpha$ to PEF during exacerbation**
Figure 3 shows that exacerbation frequency was significantly related to $\alpha$ based on stable (non-exacerbation) PEF readings, the coefficient was 0.778 exacerbation per year per unit change in alpha (95% CI 0.33-1.22; $p=0.001$). There was no difference between $\alpha$ when PEF collected during exacerbation was included or excluded (paired t-test, $p=0.131$). However, statistically significant differences did exist in mean PEF as % predicted (54.7% (SD 18.6) including exacerbations versus 55.0% (18.8) excluding exacerbations; $p=0.0046$) and in the PEF’s coefficient of variation (7.3 (5.5-10.1) versus 6.9 (5.1-10.0) respectively; $P<0.0001$).

**Effect of a long acting muscarinic anti-agonist (Tiotropium)**

Table 2 gives the baseline characteristics of the patients who completed the randomised trial of Tiotropium. Table 2 also shows that exacerbation frequency was higher in the placebo group (median 1.0 exacerbations (IQR 0-2.5)) compared to the Tiotropium group (0 exacerbations (IQR 0-1.2); $p=0.004$). The average PEF over the 300 days in the placebo group was 254 l/min (SD 91) compared to 296 l/min (SD 90; $p=0.023$). $\alpha$ was significantly lower in patients on Tiotropium than placebo, 0.87 (0.21) compared to 0.95 (0.19) respectively ($p=0.03$; see figure 4). Table 2 also shows the number of exacerbations over the 300 days on placebo as 1.75, this is equivalent to 2.13 exacerbations per patient per year and similar to the rate in the London Cohort.

**Power Analysis**
Power analysis indicated that 190 patients would be needed in each of two groups to detect the difference in exacerbation frequency reported in Table 2 with 80% power and alpha at the 5% level of significance. To detect the difference in the function $\alpha$ observed in daily PEF in the same patients and over the same time period would require only 78 patients per group, also with 80% power and a 5% significance level.

**Discussion**

This study has shown that long-term self-similarity exists in the daily PEF of patients with COPD and for the first time that the exponent $\alpha$ is associated with a measured exacerbation frequency. We also showed with data from a randomized, placebo controlled trial, that the reductions in exacerbation frequency seen with the long acting muscarinic antagonist Tiotropium are also accompanied by reductions in the value of $\alpha$ in daily PEF measurements. Thus, the exponent $\alpha$ could be potentially used as a surrogate for exacerbation frequency in clinical intervention studies. Further, the response of $\alpha$ to Tiotropium suggests that $\alpha$ is partially dependent on airway cholinergic tone.

No previous studies have applied detrended fluctuation analysis (DFA) to PEF data from COPD patients, but the technique has been used in asthma and other diseases. DFA can detect abnormal regularity in heart rate in patients with severe congestive heart failure [10, 28] and differentiate between fluctuations in the plasma glucose of healthy and diabetic patients [29]. However, it is not always obvious whether a high or low $\alpha$ indicates the pathological condition. An abnormal heart rate
with congestive heart failure is associated with a lower $\alpha$ and abnormalities in plasma glucose with a higher $\alpha$.

There is evidence in asthma that higher values of $\alpha$ are associated with a decreased risk of severe asthma episodes [16, 17]. Our results in COPD patients showed that higher $\alpha$ values were associated with an increased frequency of exacerbation, and that a pharmacological intervention which reduced exacerbation frequency also decreased the value of $\alpha$. This was forecast by Frey and colleagues who calculated that in patients with a PEF of less than 65% predicted, higher values of $\alpha$ would be associated with a greater number of obstructive events [18]. Their definition of an event as a fall in PEF below 80% predicted may not however be directly applicable to COPD as PEF changes during the exacerbations of moderate to severe COPD patients are typically much smaller.

A finding in our analysis was that exclusion of PEF data collected during exacerbations had little effect on the value of $\alpha$. It has been suggested that DFA assesses an intrinsic property of the respiratory system, and not just that more frequent exacerbations affect the variability of PEF measurements. One possible explanation for our findings is that high values of $\alpha$ are associated with more constricted airways. These airways would have little variation in diameter and PEF would be similar from one day to the next, and thus $\alpha$ would be high. If bronchomotor tone is reduced with a bronchodilator, airway calibre will increase, and there is a greater potential for variability in PEF and a loss of the self-similarity that exists in the constricted state, and hence values of $\alpha$ will be lower.
Both sympathetic and cholinergic tone affect baseline airflow and PEF. We found that an anti-cholinergic reduces $\alpha$ and further studies are required as to the effects of other bronchodilators, including LABAs and SABAs, on $\alpha$ in COPD. Cholinergic tone is thought to increase with disease severity in COPD [30]. There is also in-direct evidence that cholinergic-tone increases with hypoxia [31]. Increased cholinergic tone may also be a feature of the COPD patient with a history of frequent exacerbation, as there is a disproportional benefit of inhaled anti-cholinergic agents in patients with frequent exacerbations. Powrie et al. [25] reported a 43% reduction in exacerbation frequency with Tiotropium, compared to a placebo group who experienced 1.73 exacerbations per year. Whereas, Niewoehner et al [32] reported fewer exacerbations (1.05 exacerbation per a year) and found a 19% reduction in exacerbation frequency with Tiotropium. In the UPLIFT trial, in which patients had even fewer exacerbations (0.85 exacerbations per year in the placebo group) the reduction in exacerbation frequency with Tiotropium was only 14% [33] but this might be explained by the relatively large number of patients receiving inhaled corticosteroids alone or in combination with long-acting bronchodilators. There is also evidence that viral infection, which occurs more often in COPD patients with frequent exacerbations [3], sensitise the airway receptors with release of endogenous mediators such as histamine that cause increased parasympathetic bronchoconstriction [34].

A strength of this study is the large number of COPD patients involved and that the patients were carefully phenotyped and monitored over a prolonged period with determination of accurate exacerbation frequencies. We did not distinguish between treated and untreated exacerbations, or between exacerbations with one, two or
three major symptoms at exacerbation, as we have previously reported there to be no differences between these groups in symptom recovery times or changes in lung function [7, 20]. Additionally, we have uniquely collected daily PEF data which is rarely assessed in COPD. PEF monitoring has the advantage of being simple and cheap and can be recorded electronically on a daily basis. Our PEF measurements were not date stamped due to the technology not being available when this study started, but we see no reason why patients with frequent exacerbations should complete the diary cards when stable any differently than those with infrequent exacerbations. The best of three PEF measurements were recorded in accordance with the European Respiratory Society recommendations on measuring PEF [35] and thus our data should be comparable to asthma studies. One limitation of the study is that we were unable to allow for changes in pharmacotherapy in the London Cohort but any changes in therapy are unlikely to have altered the relationship between \( \alpha \) and exacerbation frequency. Another feature of our analysis was that we had to exclude data collected at the start of the clinical trial of Tiotropium. This was a decision taken after initially analyzing the entire data set but justifiable given that the patient had not reached a stable state after commencing treatment. The initial improvements seen in PEF were likely due to improvements in inhaler technique as patients were re-educated about taking the inhaled medication at post randomisation visits.

Negative binomial regression is commonly used to evaluate differences in exacerbation frequency. This analytical approach is used because of the distribution generated by numerous patients not experiencing any exacerbations. Consequently, the number of patients required to adequately power clinical trials is relatively large.
In contrast, the exponent $\alpha$ has a normal distribution. In this analysis, we have shown that fewer patients would need to be randomised to obtain the same statistical power, if $\alpha$ rather than exacerbation frequency had been the primary outcome measure in the Tiotropium trial that we examined. Another advantage of this function is that $\alpha$ gives a measure of exacerbation risk in patients who do not experience exacerbations over the study period. Exacerbations are also relatively difficult to determine accurately as careful monitoring is required and a significant number of exacerbations are not reported for treatment to health care professionals, causing underestimations in determining event rates [4, 36]. Use of the function $\alpha$ in clinical trials might allow evaluation of interventions that reduce exacerbations in a group of patients in whom exacerbation frequency could not be used as an outcome measure.

In conclusion, we have used the technique of detrended fluctuation analysis and shown that self-similarity exists in the daily PEF of patients with COPD. The measure ($\alpha$) is associated with exacerbation frequency and responsive to pharmacological intervention with an anti-cholinergic agent. As a surrogate marker of exacerbation frequency, $\alpha$ has the potential to reduce the number of patients required for clinical interventional trials.

**Acknowledgements.**

We would like to thank all the COPD patients who have participated in the London COPD cohort and the clinical research staff that collected the data. We are grateful for our current funding for the cohort from the Medical Research Council. We also
acknowledge the funding from Boehringer Ingelheim for the trial with Tiotropium and their permission to use the data reported in this paper.
**TABLE 1:** Baseline characteristics of the 308 COPD patients who recorded PEF on daily diary cards for at least one year.

<table>
<thead>
<tr>
<th>All COPD patients</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>68.3</td>
<td>8.4</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td>1.12</td>
<td>0.46</td>
</tr>
<tr>
<td>FEV₁ (% predicted)</td>
<td>44.5</td>
<td>16.4</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>2.52</td>
<td>0.85</td>
</tr>
<tr>
<td>FEV₁/ FVC (%)</td>
<td>45.1</td>
<td>11.8</td>
</tr>
<tr>
<td>Smoking pack years</td>
<td>50.6</td>
<td>35.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Median</th>
<th>IQR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exacerbation Frequency</td>
<td>2.04</td>
</tr>
<tr>
<td>Exacerbation Recovery (days)</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>n=</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>195</td>
</tr>
<tr>
<td>Current Smokers</td>
<td>97/304</td>
</tr>
</tbody>
</table>

Data on smoking not recorded at recruitment on 4 patients
Table 2. Patient characteristics, exacerbation frequency, $\alpha$ and mean PEF of COPD patients either on placebo or Tiotropium once daily over 12 months. P-values are for comparisons between patients on placebo or Tiotropium.

<table>
<thead>
<tr>
<th>Recorded at screening</th>
<th>Placebo N=52</th>
<th>Tiotropium N=48</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66.4 9.1</td>
<td>65.4 12.8</td>
<td>0.674</td>
</tr>
<tr>
<td>FEV$_1$ (l)</td>
<td>1.32 0.51</td>
<td>1.45 0.54</td>
<td>0.216</td>
</tr>
<tr>
<td>FEV$_1$ (% predicted)</td>
<td>51.4 14.9</td>
<td>55.7 18.3</td>
<td>0.201</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>2.21 0.76</td>
<td>2.27 0.82</td>
<td>0.701</td>
</tr>
<tr>
<td>FEV$_1$/FVC (%)</td>
<td>60 11</td>
<td>70 40</td>
<td>0.093</td>
</tr>
<tr>
<td>Smoking pack years</td>
<td>54.4 27.0</td>
<td>51.7 23.5</td>
<td>0.600</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recorded over last 300 days</th>
<th>Median</th>
<th>IQR</th>
<th>Median</th>
<th>IQR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exacerbation</td>
<td>1</td>
<td>0-2.5</td>
<td>0</td>
<td>0-1</td>
<td>0.004</td>
</tr>
<tr>
<td>Mean</td>
<td>1.75</td>
<td>1.9</td>
<td>0.81</td>
<td>1.3</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Detrended fluctuation analysis</th>
<th>Placebo</th>
<th>Tiotropium</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\alpha$</td>
<td>0.95</td>
<td>0.87</td>
<td>0.030</td>
</tr>
<tr>
<td>PEF</td>
<td>254</td>
<td>296</td>
<td>0.023</td>
</tr>
</tbody>
</table>
Figure legends

Figure 1 shows hypothetical PEF time series with $\alpha=0.5$, 1.0 and 1.5 to illustrate the increasing roughness of the time series with higher values of the exponent $\alpha$. 
Figure 2. Profile of the patients in the clinical trial of Tiotropium.

- Patients enrolled (n=237)
- Randomised
  - Tiotropium (n=69)
  - Placebo (n=73)
  - 12 months (n=48)
  - 12 months (n=52)
Figure 3. Exacerbation frequency plotted against $\alpha$, with $\alpha$ calculated using PEF with data recorded during exacerbation periods excluded.
Figure 4. Mean $\alpha$ in COPD patients on placebo and Tiotropium. Bars represent standard errors.
References


